^
Association details:
Biomarker:BRCA2 rearrangement
Cancer:Ovarian Cancer
Drug:Rubraca (rucaparib) (PARP inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Characterization of patients (pts) with long-term responses to rucaparib in recurrent ovarian cancer (OC).

Published date:
05/13/2020
Excerpt:
...pts with BRCA homozygous deletion or rearrangement had significantly longer DOR than pts with other mutation types (median 3.5 vs 0.6 y; HR = 0.30; p = 0.024)....Ten of the 13 long-term responders with BRCA wild-type OC had high genome-wide LOH (≥16% LOH), a genomic scar indicative of homologous recombination deficiency, including OC associated with BRCA1 hypermethylation (n = 2) and RAD51C/D mutations (n = 2).
DOI:
10.1200/JCO.2020.38.15_suppl.6015